ABSTRACT
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the liver generally associated with obesity. The clinical spectrum of the disease may vary from asymptomatic simple steatosis to cirrhosis (1) . It is the most common cause of endstage liver disease in adolescents in the Western countries and an increasing indication of liver transplantation in adults in the United States of America (2) .
The development and progression of NAFLD is related to the interactions between genetic, epigenetic, and environmental factors (3) . Environmental factors, such as unhealthy diet and low physical activity, can promote the epigenetic reprogramming of the host genome ultimately causing phenotypic changes in the organism (4) . For these reasons, environmental factors represent the core point of the prevention and treatment of NAFLD.
It has been shown that gut microbiota composition may be influenced by the environmental factors, and dysbiotic gut microbiota may cause intra-hepatic fat accumulation. Therefore, the modulation of interaction between the gut microbiota and liver has become the main target for the management of NAFLD in recent years (4) . Beneficial effects of probiotics, prebiotics, and synbiotics on gut microbiota have been confirmed in previous experimental and human studies (5) .
ance and low-grade efficiency indicate the use of the combination with pharmacological medications (3) . Various pharmacological medications have been used in addition to lifestyle modifications, but drawing a firm conclusion regarding the efficiency of these medications was challenging (6) . Therefore, we aimed to analyze the efficiency of a novel treatment approach, long-term synbiotic supplementation, in addition to lifestyle changes in children with NAFLD.
MATERIALS AND METHODS
This was a longitudinal study of 4 months including patients with NAFLD (n=30) and healthy children (n=30). The diagnosis of NAFLD was made based on the physical findings (obesity) along with sonographic findings of fatty liver disease and/ or elevated liver enzymes (alanine aminotransaminase [ALT] >45 U/L) (1). Patients were excluded if they had other causes of liver diseases. Patients were also excluded if they had any other known systemic diseases, consumed alcohol, or used any drugs for the treatment of NAFLD, and previously and currently used pre-and/or probiotics and antibiotics for any reason within 6 months.
Children with NAFLD were given 1 capsule/day of synbiotics (Maflor plus capsules ® ) that contained 7×10 9 colony-forming unit (CFU) active probiotics (Bifidobacterium lactis, Lactobacillus acidophilus, and Lactobacillus casei) and 100 mg chicory inulin for 4 months. In addition to the medical treatment, patients were prescribed a low-calorie diet (approximately 10%-20% low calorie according to their age with 50%-60% carbohydrates, 20%-30% fat: two-third saturated and one-third unsaturated, and 10%-20% protein) and a moderate exercise program (aerobic exercise 30-45 min/d at least 3 times a week). None of the patients received antibiotics during the follow-up. Compliance to diet and exercise program was checked at each visit by face-to-face questionnaire the second author of the manuscript.
Anthropometric parameters were analyzed, and biochemical analysis and ultrasonographic examination were performed at baseline and 4 months later in all (patients). Body mass index (BMI) and standard deviation scores were calculated using the Turkish reference data (7). Total body fat level was measured using a Tanita BC 418 ® device (Tanita, Tokyo, Japan). 
Biochemical Measurements
A part of the collected blood was centrifuged and stored at -80°C for further analysis of the levels of TNF-α, TAS, TOS, and zonulin. Specific sandwich enzyme-linked immunosorbent assay (ELISA) was used to determine the levels of TNF-α and zonulin (TNF-α-EASIA Kit, DIAsource, Belgium, and CusaBio, China, respectively). TOS of serum was determined using a novel automated measurement method as previously described (9) . Serum TOS levels were calculated in µmol hydrogen peroxide (H 2 O 2 ) equivalent/L. TAS of the serum was determined using a novel automated measurement method developed by Erel (10) . Serum TAS levels were calculated in mmolTrolox equivalent/L. Stool samples were stored at -20C for the further analysis of calprotectin levels. Sandwich ELISA was used for the analysis of calprotectin levels using IDK ® Calprotectin ELISA kits.
Liver Ultrasound
Liver ultrasound was performed by the same experienced radiologist using a Toshiba Aplio A500 TUS scanner equipped with 6C1 convex probe. Liver steatosis was graded as normal (grade 0), mild (grade 1), moderate (grade 2), and severe (grade 3) according to sonographic findings as defined elsewhere (11) . The response to the treatment was defined as decrease in liver steatosis ≥1 grade at end of 4 months compared to baseline.
Statistical Analysis
Statistical analysis was performed using Statistical Package for Social Sciences version 23 (IBM Corp.; Armonk, NY, USA). Differences between groups were calculated using an independent samples t-test (Student's t-test) for the normally distributed data and the Mann-Whitney U test for data that was not normally distributed. Chi-square test was used for the comparisons of qualitative data. Correlations between variables were calculated using linear regression. Values of p<0.05 were considered significant. Informed consent for participating in the study was obtained from parents of all cases and approved by the ethics committee (2014/97). The study was funded by the Scientific Research Projects Unit (TTU-2015-5321).
RESULTS
Thirty patients were planned to be included the study but two patients were lost to follow-up during the study period, and final analysis were performed in 28 patients. Table 2 shows the baseline anthropometric parameters and biochemical measurements of the children with NAFLD and the healthy control group.
As expected, BMI, BMI Z-score, total body fat, serum ALT and aspartate aminotransaminase (AST ), TC, TG, LDL, VLDL, and HOMA-IR levels were higher in children with NAFLD compared to healthy controls at baseline (p<0.05 for all). Additionally, serum ethanol, CRP, TNF-α, zonulin levels, and fecal calprotectin levels were higher in patients with NAFLD compared to healthy controls (p<0.05 for all). In the complete study group (n=58), ALT levels positively correlated to serum ethanol levels (p=0.04, r=0.377). In addition, ethanol levels positively correlated to TNF-α levels (p=0.003, r=0.368), and fecal calprotectin levels positively correlated to zonulin levels (p=0.0001, r=0.683; Figure 1 ). Figure 2) . Additionally, the likelihood of "normal+grade 1 fatty liver" was increased from 17.9% (n=5) to 50% (n=14) at the end of the treatment (p=0.01, odds ratio [OR]: 4.6, 95% CI: 1.36-15.5).
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After synbiotic supplementation, serum ALT and AST levels were significantly decreased from 56.3±39.8 U/L to 35.58±21.73 U/L (p=0.001) and from 45±22.9 U/L to 41.46±37.95 (p=0.02), respectively. Normalization of ALT (<45 U/L) was observed in 9 (60%) of 15 patients whose ALT levels were previously high. 
Effects of Synbiotics on

Effects of Synbiotics on Other Parameters
Effects of synbiotic supplementation on TNF-α, CRP, ethanol, zonulin, TAS, TOS, and fecal calprotectin are shown in Table  3 . Levels of TNF-α (9.92±7.48 pg/mL vs. 8.46±7.44 pg/mL, p=0.01), CRP (0.51±0.44 mg/dL vs. 0.39±0.38 mg/dL, p=0.003), and ethanol (4.93±3.95 mg/dL vs. 0.92±1.43 mg/dL, p=0.001) were decreased, and TAS levels (1.43±0.35 mmoltroloxEq/L vs. 1.84±0.43 mmoltroloxEq/L, p=0.02) were increased at the end of the treatment, but no significant difference was found in the remaining parameters.
Baseline characteristics of the patients who responded to the synbiotic supplementation (n=19) were compared with unresponsive patients (n=9) and found that baseline ALT levels were low (median, range: 50 U/L, 14-167 U/L vs. 87 U/L, 19-150 U/L; p=0.049) in patients who responded to the supplementation. Additionally, we analyzed the changes from baseline to the end of the treatment within the groups (responsive vs. nonresponsive patients) /median, minimum and maximum) and found that the decrease in BMI (-2.3 kg/m (Table 4) .
A post-hoc power analysis of our findings revealed that the power of our study was 86.3% (α=0.05, expected beneficial effect of probiotics=40%, sample size=28). Table 4 . Changes in some parameters from baseline to the end of the treatment
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DISCUSSION
In this study, we found that (i) apart from anthropometric parameters, liver enzymes, and lipid profile, patients with NAFLD had increased ethanol levels, systemic and intestinal inflammation markers, and intestinal permeability when compared the healthy children; (ii) synbiotic supplementation in addition to lifestyle changes decreased liver enzymes and improved fatty liver in approximately two-third of the patients; (iii) anthropometric parameters related to obesity decreased after synbiotic supplementation in addition to lifestyle changes; (iv) synbiotic supplementation improved TC and LDL levels, inflammatory markers, and ethanol levels; (v) mild elevation of ALT might be a marker of response to the synbiotic supplementation; and (vi) decrease in LDL levels and inflammation (CRP levels) might be effective in the improvement of fatty liver in addition to decrease in BMI.
In previous studies, it has been shown that obese patients with NAFLD had altered intestinal microbiota and intestinal barrier dysfunction due to environmental factors (high-fat/fructose diet) that cause low-grade systemic inflammation and metabolic endotoxemia (4). Circulating zonulin concentration was shown to increase in children and adolescents with NAFLD and correlated to the severity of hepatic steatosis (12) . Additionally, other biomarkers of intestinal barrier dysfunction, such as occludin and tight junction (TJ) proteins, were also shown to increase in patients with NAFLD (5,12,13). In our study; we did not find any correlation to the severity of steatosis assessed by liver ultrasound; however, we found that it was correlated with intestinal inflammation markers. Similar results were found by Zak-Gołąb A et al. (13) ; zonulin concentration was correlated with intestinal inflammation and systemic microinflammation in obese subjects.
Ethanol is one of the major hepatotoxic microbiota-associated metabolite that is delivered to the portal circulation; moreover, it contributes to the accumulation of triglyceride and formation of reactive oxygen species in the liver in patients with altered intestinal microbiota (14) . Increased levels of ethanol have been detected in animal and human studies with NAFLD (15). Zhu and colleagues compared NAFLD patients with obese and healthy controls and found that patients with NAFLD had significantly elevated ethanol levels compared to obese children without NAFLD and healthy controls. They showed that the difference was associated with the difference in the diversity of the microbiota between the groups; patients with NAFLD had ethanolproducer-dominant microbiota, including Proteobacteria/Enterobacteriaceae/Escherichia, compared to obese children without NAFLD and healthy controls (16) . We found that the levels of ethanol were correlated to the TNF-α and ALT levels, suggesting the role of ethanol in the secretion of inflammatory cytokines (TNF-α) and progression of inflammation in the liver (17) .
In our study, we found that systemic and intestinal inflammation markers are increased in children with NAFLD. In a recent study, the levels of pro-inflammatory cytokines and endotoxinrelated parameters were shown to increase in patients with NAFLD, and pro-inflammatory cytokine levels were correlated with the histological severity of NAFLD (18) . Fecal calprotectin levels were studied in obese children, and a correlation was found with BMI and abnormal oral glucose tolerance test in children (19) .
The effects of probiotics and synbiotics on NAFLD have been studied previously. Vajro et al. (20) randomized 20 children with NAFLD for probiotic supplementation and placebo for 8 weeks and found that liver enzymes and serum antibodies to antipeptidoglycan-polysaccharide polymers were decreased in the probiotic-supplemented group compared to the placebo group at the end of 8 weeks. They concluded that probiotic supplementation may be used as a therapeutic tool in obese children with NAFLD who were non-compliant to lifestyle modifications. Alisi et al. (21) studied the effect of VSL#3 supplementation (450 billion colonies/sachet of viable, lyophilized bifidobacteria, lactobacilli, and Streptococcus thermophilus) on NAFLD in children. They found that 4 months of VSL#3 supplementation improved fatty liver and BMI in children by increasing the glucagon-like peptide 1 levels. Famouri et al. (22) analyzed the effect of a probiotic capsule (mixture of 4 probiotics strain) for 12 weeks in children with NAFLD and found an improvement on the sonographic grade of fatty liver and lipid profile at the end of 12 weeks.
The effects of synbiotic supplementation in patients with NAFLD was studied in adults; it was shown that 28 weeks of synbiotic supplementation (7 strains probiotic and fructooligosaccharide) in addition to lifestyle modifications was superior to lifestyle modifications alone for the treatment of NAFLD. Additionally, they showed that synbiotic supplementation attenuates inflammatory markers and decreases BMI and waistto-hip ratio that was evident at week 14 and sustained until the end of the treatment (23) . Similar results were found by Malaguarnera et al. (24) in a study on adults; Bifidobacterium longum with fructooligosaccharide and lifestyle modification for 24 weeks significantly reduces steatosis and the non-alcoholic steatohepatitis (NASH) activity index when compared to lifestyle modification alone. In our study, we found that 4 months of synbiotic supplementation in addition to lifestyle changes decreases the sonographic grade of fatty liver in approximately two-thirds of the children.
The effect of probiotic supplementation in patients with NAFLD was analyzed in a meta-analysis, and it was revealed that in addition to improvement in the grade of fatty liver, probiotics reduce liver enzymes, TC, TNF-α, and CRP and improve insulin resistance (25) . Effects on BMI and other anthropometric parameters were not evident in adult patients, whereas it was more evident in children (26) . Similar results were found in our study, except in improvement in insulin resistance. Additionally, we found that synbiotic supplementation reduces LDL levels. Safavi et al. (27) showed a significant difference in all lipid parameters after 8 weeks of synbiotic supplementation in obese children. In contrast, Ipar et al. (28) found significant improvement only in TC and LDL levels and not in TG levels after synbiotic supplementation, as in our study. Effects of probiotics or synbiotics on TG levels have some controversies; Gao et al. (26) revealed that lipid-lowering effect of probiotics or synbiotics may vary in different countries/ethnicities. Additionally, types of the strain in probiotics, types of the prebiotics used for the study, and the duration of the treatment may affect lipidlowering property (29, 30) . We found that improvement in lipid parameters, particularly in LDL levels, are important for the improvement of fatty liver in symbiotic-supplemented children. High LDL levels are a risk factor for the cardiovascular disease in patients with NAFLD (30) . Decrease in LDL levels with the synbiotic supplementation will improve both fatty liver and future cardiovascular complications in children with NAFLD.
The limitations of our study were (i) the lack of liver biopsy for the assessment of the severity of steatosis and fibrosis. Since the participants were obese and did not have any serious clinical hepatic condition, we did not consider liver biopsy due to its invasive nature and limited the examinations to sonography and biochemical parameters; (ii) lack of microbiota analysis and (iii) a randomized control group limited the study; however, it was considered unethical to prescribe long-term "placebo plus lifestyle changes" for grade II-III fatty liver patients. It was shown that adherence to lifestyle modifications is poor in children; therefore, "placebo plus lifestyle changes" may worsen the steatosis if the patients do not adhere to the recommendations (31, 32) . The main strengths of our study were its novelty in the pediatric age group and that we used detailed biochemical analysis.
In conclusion, we showed that synbiotic supplementation in addition to lifestyle changes is effective in children with NAFLD. As shown in our study and previous studies, there is no suspicion for the positive effects of probiotics or synbiotics that added to lifestyle changes on NAFLD. As a consequence of our study, further prospective long-term studies are needed to analyze effect of probiotics or synbiotics on obesity-related cardiovascular complications, such as atherosclerosis and stroke.
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